Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123535 · ClinicalTrials.gov registry record · NA
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
A NA study of Undifferentiated Pleomorphic Sarcoma, sponsored by Matthew Bucknor.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04123535 is a NA study of Undifferentiated Pleomorphic Sarcoma that is actively recruiting participants, run by Matthew Bucknor. The registered enrollment target is 20 participants, below the 111-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04123535, a NA study of Undifferentiated Pleomorphic Sarcoma, is actively recruiting participants, sponsored by Matthew Bucknor.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.
Conditions Studied
Interventions
- DEVICE ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04123535
The ClinicalTrials.gov registry entry for NCT04123535 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (82% lower). The listed sponsor is Matthew Bucknor, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Undifferentiated Pleomorphic Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) is the first listed.
NCT04123535 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04123535 about?
NCT04123535 is a clinical study titled "Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma". This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.
What is the current status of trial NCT04123535?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2020-01-23. Estimated completion is 2026-06-30.
What conditions does trial NCT04123535 study?
This clinical trial studies the following conditions: Undifferentiated Pleomorphic Sarcoma.
What interventions are being tested in trial NCT04123535?
The interventions under investigation include: ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) (DEVICE).
Who is sponsoring clinical trial NCT04123535?
This trial is sponsored by Matthew Bucknor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04123535 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Undifferentiated Pleomorphic Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
RECRUITING · Phase 2
-
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
ACTIVE NOT RECRUITING · Phase 2
-
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.